electroCore, Inc. (NASDAQ:ECOR) Short Interest Up 64.1% in October

electroCore, Inc. (NASDAQ:ECOR) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 43,000 shares, an increase of 64.1% from the October 15th total of 26,200 shares. Based on an average daily volume of 50,200 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.8% of the company’s stock are sold short.

Institutional Trading of electroCore

Several hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC raised its holdings in electroCore by 689.1% in the 3rd quarter. International Assets Investment Management LLC now owns 535,146 shares of the company’s stock valued at $3,864,000 after acquiring an additional 467,326 shares in the last quarter. Renaissance Technologies LLC raised its holdings in electroCore by 3.4% in the 2nd quarter. Renaissance Technologies LLC now owns 68,786 shares of the company’s stock valued at $442,000 after acquiring an additional 2,270 shares in the last quarter. Finally, HighTower Advisors LLC acquired a new position in electroCore in the 3rd quarter valued at $255,000. 26.74% of the stock is owned by institutional investors and hedge funds.

electroCore Trading Down 19.6 %

Shares of NASDAQ ECOR opened at $10.94 on Friday. electroCore has a 12 month low of $5.02 and a 12 month high of $14.20. The stock has a 50 day moving average of $8.89 and a 200-day moving average of $7.22. The company has a market capitalization of $70.56 million, a P/E ratio of -5.98 and a beta of 0.56.

About electroCore

electroCore, Inc, a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.